In an experimental model, auranofin was shown to inhibit NF-κB activation in synoviocytes derived from rheumatoid arthritis patients, resulting in decreased production of pro-inflammatory cytokines such as TNF-α [35,36]. The gene discussed is TNF; the disease is rheumatoid arthritis.